Date | Price Target | Rating | Analyst |
---|---|---|---|
7/19/2024 | $15.00 | Buy | Jefferies |
10/23/2023 | $13.00 → $9.00 | Neutral → Underperform | BofA Securities |
6/23/2023 | $11.00 | Equal Weight → Underweight | Barclays |
4/24/2023 | $11.00 | Overweight → Equal Weight | Barclays |
2/17/2023 | $16.00 → $14.00 | Outperform → Market Perform | BMO Capital Markets |
1/27/2023 | $13.00 → $15.00 | Hold → Buy | Jefferies |
11/10/2022 | $9.00 → $12.00 | Sell → Neutral | UBS |
11/8/2022 | $10.00 | Underweight → Neutral | Piper Sandler |
These ten large-cap stocks were the best performers in the last week. Are they in your portfolio? Warner Bros. Discovery, Inc. (NASDAQ:WBD) stock escalated 18.28% after a report that the company had discussed plans to split its digital streaming and studio businesses from its legacy television networks. MicroStrategy Inc.’s (NASDAQ:MSTR) stock gained 16.74% last week amid a rise in Bitcoin’s price. D.R. Horton, Inc. (NYSE:DHI) shares surged 12.91% after the company reported better-than-expected Q3 financial results and revised FY24 guidance. The company also authorized a new $4 billion share repurchase. Few analysts raised the price forecasts on the stock. Coinbase Global Inc.’s
Jefferies analyst Glen Santangelo reinstates Viatris (NASDAQ:VTRS) with a Buy and announces $15 price target.
The clinical trial is a bridging study requiring a limited number of Japanese patients to participate in a study similar in design to that of the global NefIgArd trial. IgA nephropathy is a designated retractable disease in Japan, with an estimated 33,000 patients in Japan* assumed to be suffering from this disease and with limited treatment options for IgAN patients in this country.
8-K - Viatris Inc (0001792044) (Filer)
144 - Viatris Inc (0001792044) (Subject)
10-Q - Viatris Inc (0001792044) (Filer)
SC 13G/A - Viatris Inc (0001792044) (Subject)
SC 13G - Viatris Inc (0001792044) (Subject)
SC 13G/A - Viatris Inc (0001792044) (Subject)
Jefferies resumed coverage of Viatris with a rating of Buy and set a new price target of $15.00
BofA Securities downgraded Viatris from Neutral to Underperform and set a new price target of $9.00 from $13.00 previously
Barclays downgraded Viatris from Equal Weight to Underweight and set a new price target of $11.00
PITTSBURGH, Sept. 10, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS, ", Viatris", or the ", Company", ))) announced today that the previously announced cash tender offers (the "Any and All Tender Offers" and each, an "Any and All Tender Offer") of Viatris and its subsidiary Mylan Inc. ("Mylan" and, together with Viatris, the "Offerors" and each, an "Offeror") for any and all of the outstanding 1.650% Senior Notes due 2025 issued by Viatris (the "Viatris Notes") (CUSIP No. 92556VAB2/ISIN US92556VAB27) and any and all of the outstanding 2.125% Senior Notes due 2025 issued by Mylan (the "Mylan Notes" and, together with the Viatris Notes, the "Any and All Notes") (ISIN XS1801129286/Common Code
PITTSBURGH, Sept. 10, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS, ", Viatris", or the ", Company", ))) announced today the pricing terms of the previously announced cash tender offers (the "Any and All Tender Offers" and each, an "Any and All Tender Offer") of Viatris and its subsidiary Mylan Inc. ("Mylan" and, together with Viatris, the "Offerors" and each, an "Offeror") for any and all of the outstanding 1.650% Senior Notes due 2025 issued by Viatris (the "Viatris Notes") and any and all of the outstanding 2.125% Senior Notes due 2025 issued by Mylan (the "Mylan Notes" and, together with the Viatris Notes, the "Any and All Notes"). The terms and conditions of the Any and All Tender Of
PITTSBURGH, Sept. 4, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS, ", Viatris", or the ", Company", ))) announced today that it and its subsidiaries, Mylan Inc. ("Mylan") and Utah Acquisition Sub Inc. ("Utah Acquisition" and, together with Viatris and Mylan, the "Offerors" and each, an "Offeror"), have commenced tender offers (each individually, with respect to a series of notes, a "Tender Offer" and, collectively, the "Tender Offers") to purchase for cash (1) any and all of the outstanding 1.650% Senior Notes due 2025 issued by Viatris (the "Viatris Notes"), (2) any and all of the outstanding 2.125% Senior Notes due 2025 issued by Mylan (the "Mylan Notes" and, together with the Viatris No
PITTSBURGH, June 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that as part of its ongoing Board refreshment efforts, Rogerio Vivaldi Coelho, M.D., has been appointed as the newest member of its Board of Directors. Dr. Vivaldi will serve as a member of the recently reestablished Science and Technology Committee of the Board of Directors. "We are pleased to welcome Dr. Vivaldi to our Board of Directors," said Melina Higgins, Chair of the Board, Viatris. "We believe his proven expertise and long track record of success will enhance the efforts of the Board across a range of areas, in particular with regards to our Science and Technology Commit
PITTSBURGH, April 15, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company's Executive Leadership Team, effective today. Le Goff is an accomplished biotechnology and pharmaceutical executive with more than 25 years of experience leading and building highly successful teams globally. She is a visionary and entrepreneurial leader with a strong scientific background and experience across multiple markets and therapeutic areas. Prior to joining Viatris, Le Goff was President and Chief Executive Officer of Imunon, a clinical-stage biotechnology
Company thanks Sanjeev Narula for his role in the successful execution of Viatris' Phase 1 strategy; Narula will support a smooth CFO transition prior to his departure on March 1, 2024 PITTSBURGH, Dec. 15, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that, as it prepares to enter Phase 2 of its strategic plan, Theodora "Doretta" Mistras has been appointed Chief Financial Officer (CFO) effective March 1, 2024, and Philippe Martin has been appointed Chief R&D Officer with immediate effect. Current Viatris CFO Sanjeev Narula, who h
PITTSBURGH, Aug. 8, 2024 /PRNewswire/ -- Strong Results Demonstrate Power of Company's Diversification, Execution and Growing Base Business Total Revenues of $3.8 Billion and Operational Revenue Growth of ~2% on a Divestiture-Adjusted Basis[1]Strong New Product Revenues in the Quarter of $210 Million Drove Growth Across SegmentsU.S. GAAP Net Loss was $326 Million; Adjusted EBITDA Grew ~2% to $1.2 Billion on a Divestiture-Adjusted Basis; U.S. GAAP Diluted EPS was a Loss of $0.27 per Share; Adjusted EPS Grew ~3% to $0.69 per Share on a Divestiture-Adjusted Basis[2]Completion of Divestitures Marks Inflection Point in Company's Move Towards Accelerated Growth and Shareholder ReturnRaises 2024 F
PITTSBURGH, Aug. 6, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that on August 5, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on September 13, 2024, to shareholders of record as of the close of business on August 23, 2024. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provi
Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth PITTSBURGH, July 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that it has closed the divestiture of its Over-the-Counter (OTC) business to Cooper Consumer Health, a leading European over-the-counter drug manufacturer and distributor, bringing to substantial completion all previously announced divestitures. In October, the Company announced it had entered into agreements to divest substantially all of its OTC business, as well as its Women's Healthcare business, its Active Pharmac
4 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)